A Phase II, Open-label, Study in Subjects With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib

Trial Profile

A Phase II, Open-label, Study in Subjects With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Dabrafenib (Primary) ; Trametinib (Primary)
  • Indications Adenocarcinoma; Biliary cancer; Gastrointestinal stromal tumours; Germ cell and embryonal neoplasms; Glioma; Hairy cell leukaemia; Multiple myeloma; Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms ROAR
  • Sponsors GlaxoSmithKline; Novartis Pharma A.G.
  • Most Recent Events

    • 06 Jun 2017 Results (n=16) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 03 May 2017 Planned number of patients changed from 135 to 225.
    • 24 Oct 2016 Planned End Date changed from 1 Mar 2020 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top